4. Boutin P, Chevre JC, Hani EH et al. (1997) . The JDF Unit for islet cell antibodies was born [7] and numerous publications have since reported islet cell antibody concentrations in JDF Units. The last islet cell antibody workshop showed that although the concordance in the islet cell antibody analysing community had improved overall, the islet cell antibody determinations were far from perfect [6] . Subsequently, the JDF islet cell antibody Standard (sample 673) was also used in the IDW-supported proficiency testing carried out by N. Maclaren in Gainesville, Florida, USA.
More recently the JDF islet cell antibody standard has also been found useful in standardizing the radioimmunoassays for cloned autoantigens [8, 9] . The JDF islet cell antibody standard is positive for both glutamic acid decarboxylase (GAD) 65 and protein tyrosine phosphatase-2 (IA-2) autoantibodies, but not for insulin autoantibodies. In addition to the IDW Workshops and the IDW Proficiency testing, more than 50 laboratories following individual requests to one of us (L) have been given 1±10 ml of the 673 plasma usually to help researchers get started with islet cell antibody assays. It is obvious that at this rate of consumption the JDF islet cell antibody standard would not last much longer.
In 1995 there were only about 500 ml left of the JDF islet cell antibody standard. To make maximum use of this last volume, the Juvenile Diabetes Foundation International supported a project to prepare 4000 ampoules of the JDF islet cell antibody standard, freeze-dried and sealed under nitrogen. This task was carried out by the National Institute of Biological Standards and Control (NIBSC, Potters Bar, Herefordshire, UK), which is the WHO International Laboratory for Biological Standards. The NIBSC is accredited for biological standard activities (BS EN ISO 9001) and develops, evaluates and distributes a wide range of international biological standards. The standards are prepared and distributed on behalf of the WHO and are used by scientists involved in biomedical research, industry and control authorities.
The NIBSC has prepared 4000 ampoules of the JDF islet cell antibody standard. To fulfil the WHO requirements for a biological standard preparation, a number of expert laboratories have carried out a WHO/JDF Collaborative Study. The aim of this study was to assess the suitability of the ampouled preparations of the JDF islet cell antibody standard (sample 673) to serve as an international standard (IS) for the immunoassay of human islet cell autoantibodies. The collaborative study will also assess the relative activity of the ampouled preparations in different assays and assess the influence of individual assay formats on the estimates of potency. Once this workshop has been completed it is expected that the JDF islet cell antibody standard will be promoted to a JDF/WHO islet cell antibody standard. The NIBSC will store and distribute the JDF/WHO islet cell antibody standard and keep a tally of the different laboratories requesting ampoules. For obvious reasons there will be a limitation on the number of ampoules which can be distributed per year. It is expected that each laboratory will establish its own in-house autoantibody standard preparation to be matched to the WHO/JDF islet cell antibody standard.
The WHO/JDF islet cell antibody standard should be useful in the continuing task to improve assay performance by the Immunology of Diabetes Society (IDS). The IDS which has an antibody standardization committee is planning to conduct additional studies to determine the best way to use the WHO/JDF Standard to improve inter-laboratory concordance and intra-laboratory reproducibility for measurement of ICA, GAD and IA-2 antibodies. There is currently no reference standard for insulin autoantibodies and attempts will be made by the IDS to rectify this as soon as possible. The WHO/JDF islet cell antibody standard should also help individual laboratories to improve assay performance in the IDS-supported proficiency testing activity, which is currently being reorganized. Is plasma homocysteine related to albumin excretion rate in patients with diabetes mellitus?
Dear Sir, The paper by Chico et al. argues that an increased albumin excretion rate (AER), rather than creatinine clearance, influences plasma homocysteine concentrations in diabetic patients [1] . In our view, their conclusions are not fully validated by the data they present. Firstly, looking at Figure 1 , the differences in homocysteine concentrations in patients with Type I (insulin-dependent) and Type II (non-insulin-dependent) diabetes mellitus with varying degrees of albuminuria are not statistically significant, as long as patients with high serum creatinine concentrations (> 120 umol/l) are excluded. Nowhere is it shown that microalbuminuric patients have statistically significantly higher homocysteine concentrations than patients with normoalbuminuria. Only when Type I and Type II diabetic patients are taken together, do macroalbuminuric patients have higher homocysteine concentrations than normoalbuminuric patients. Differences in Cockroft-Gault derived creatinine clearances are not given for this combined group but the subgroups show progressively lower clearances in patients with micro-and macroalbuminuria. That these differences are not statistically significant does not rule out that they influence homocysteine concentrations. Why are the non-significant differences in creatinine clearance judged as irrelevant, whereas the equally non-significant differences in homocysteine concentrations are interpreted as important results?
The multivariate analysis of determinants of homocysteine concentrations suggests that neither B-vitamin concentrations nor creatinine clearance but only albumin excretion rate (and age in Type II diabetes) influence homocysteine concentrations in the diabetic subgroups. It is generally accepted that the maximum number of variables in a multiple regression model, stepwise or not, should never be more than 10 % and preferably less than 5 % of the number of patients. Since the authors state that`all variables' were included, it appears that around 15 variables were used in models with 75 (Type I) and 90 (Type II) patients. This makes the analyses unstable, and prone to spurious results.
The most important potential source of error is that determinants and complications of increasing homocysteine concentrations could have been mixed-up. Albuminuria is seen more often in the presence of cardiovascular risk factors, like hypertension, smoking, obesity, and dyslipidaemia. It is certainly plausible that the`new' vascular risk factor hyperhomocysteinaemia causes albuminuria, rather than the other way round. If this is so, then a complication of increasing homocysteine concentrations is analysed as a co-variate of determinants of these concentrations, which leads to erroneous results. In contrast with the situation of bivariate tests, the set-up of a multiple regression analysis automatically introduces assumptions about the direction of causality between the independent and the dependent variable. We would like to invite the authors to produce the results of a more logical model with albumin excretion rate as the dependent variable and homocysteine as one of the independent variables, together with other known determinants of albuminuria.
The vast majority of studies in both diabetic and non-diabetic subjects has found creatinine clearance to be an important determinant of homocysteine concentrations. The results are certainly more equivocal for albuminuria. The central question of whether there is a relation between albumin excretion rate and homocysteine concentrations, independent of creatinine clearance, remains unresolved.
Yours sincerely, Y. M. Smulders, C. B. Brouwer, J. Silberbusch
